Table 1.
Demographics and clinical data (N = 82)
| No Relapse (n = 44; 53.7%) | Relapse (n = 38; 46.3%) | All (n = 82) | ||||
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Sex | ||||||
| Female | 26 | 59.1% | 18 | 47.4% | 44 | 53.7% |
| Male | 18 | 40.9% | 20 | 52.6% | 38 | 46.3% |
| Race | ||||||
| Caucasian | 34 | 77.3% | 31 | 81.6% | 65 | 79.3% |
| Black | 6 | 13.6% | 4 | 10.5% | 10 | 12.2% |
| Asian | 4 | 9.1% | 3 | 7.9% | 7 | 8.5% |
| Ethnicity | ||||||
| Non-Hispanic | 13 | 29.5% | 13 | 34.2% | 26 | 31.7% |
| Hispanic | 31 | 70.5% | 25 | 65.8% | 56 | 68.3% |
| Age at symptom onset | 14.1 | (3.5) | 15.6 | (4.6) | 14.8 | (4.1) |
| Age at diagnosis | 16.5 | (4.1) | 17.9 | (5.1) | 17.2 | (4.6) |
| Age at Therapy | 16.8 | (4.1) | 18.4 | (4.9) | 17.5 | (4.5) |
| Δ Age at Symptom Onset and Age at Diagnosis | 2.4 | (1.9) | 2.3 | (1.8) | 2.4 | (1.8) |
| Δ Age at Therapy and Age at Diagnosis* | 0.3 | (0.5) | 0.5 | (0.6) | 0.4 | (0.6) |
| Δ Age at Therapy and Age at Symptom Onset | 2.7 | (2.1) | 2.8 | (1.7) | 2.8 | (1.9) |
| Time (months) to Symptom Peak | 3.7 | (2.5) | 3.3 | (2.5) | 3.5 | (2.5) |
| Trigger Present | 20 | 45.5% | 20 | 52.6% | 40 | 48.8% |
| Type of Trigger | ||||||
| Infection | 9 | 20.5% | 7 | 18.4% | 16 | 19.5% |
| Change of School/Work/Home Environment | 6 | 13.6% | 5 | 13.2% | 11 | 13.4% |
| Loss of Family/Caregiver/Friend | 2 | 4.5% | 2 | 5.3% | 4 | 4.9% |
| Death | 1 | 2.3% | 2 | 5.3% | 3 | 3.7% |
| Change in Residence | 0 | 0.0% | 2 | 5.3% | 2 | 2.4% |
| Abuse | 1 | 2.3% | 1 | 2.6% | 2 | 2.4% |
| Medical Change | 1 | 2.3% | 1 | 2.6% | 2 | 2.4% |
| Disease Biometrics | ||||||
| Probable DSRD Criteria | 17 | 38.6% | 13 | 34.2% | 30 | 36.6% |
| History of Personal Autoimmune Disease | 18 | 45.0% | 15 | 46.9% | 33 | 45.8% |
| Serum Cytokines | 7 | 26.9% | 13 | 54.2% | 20 | 40.0% |
| Catatonia | 30 | 68.2% | 30 | 78.9% | 60 | 73.2% |
| EEG Abnormal* | 7 | 17.5% | 12 | 37.5% | 19 | 26.4% |
| MRI Abnormal** | 4 | 10.0% | 12 | 37.5% | 16 | 22.2% |
| Lumbar Puncture Abnormal** | 3 | 7.5% | 9 | 28.1% | 12 | 16.7% |
| Any Neurodiagnostic Study Abnormal** | 9 | 22.5% | 20 | 62.5% | 29 | 40.3% |
| Psychotropic Medications at Baseline | 35 | 79.5% | 30 | 78.9% | 65 | 79.3% |
| Benzodiazepines | 22 | 50% | 17 | 44.7% | 39 | 47.6% |
| SSRI/SNRIs | 17 | 38.6% | 10 | 26.3% | 27 | 32.9% |
| Antipsychotics | 8 | 18.2% | 7 | 18.4% | 17 | 20.7% |
| Anticonvulsants | 2 | 4.5% | 5 | 13.1% | 7 | 8.5% |
| Mood Stabilizers | 3 | 6.8% | 0 | 0% | 3 | 3.6% |
| Prior Immunotherapy | 3 | 6.8% | 1 | 2.6% | 4 | 4.9% |
| IVIg Brand | ||||||
| Gammaguard | 27 | 61.4% | 28 | 73.7% | 55 | 67.1% |
| Octagam | 11 | 25.0% | 7 | 18.4% | 18 | 22.0% |
| Privagen | 6 | 13.6% | 3 | 7.9% | 9 | 11.0% |
| IVIg Duration | 7.5 | (2.4) | 7.8 | (2.1) | 7.6 | (2.3) |
| Baseline Clinical Features | ||||||
| 25 Foot Walk** | 9.4 | (4.5) | 12.3 | (6.4) | 10.7 | (5.6) |
| Bush Francis Severity Score | 16.6 | (9.9) | 19.5 | (10.9) | 17.9 | (10.4) |
| CGI Severity of Illness** | 3.3 | (1.3) | 4.1 | (1.5) | 3.6 | (1.4) |
| NPI Total Score** | 18.7 | (5.7) | 21.8 | (5.9) | 20.1 | (6.0) |
| NPI Delusions | 3.8 | (1.9) | 3.6 | (1.6) | 3.7 | (1.8) |
| NPI Hallucinations* | 1.2 | (1.4) | 1.8 | (1.7) | 1.5 | (1.5) |
| NPI Agitation | 2.1 | (1.4) | 1.9 | (1.6) | 2.0 | (1.5) |
| NPI Anxiety | 0.8 | (0.9) | 0.6 | (0.7) | 0.7 | (0.8) |
| NPI Apathy* | 2.5 | (1.5) | 3.1 | (1.6) | 2.8 | (1.5) |
| NPI Irritability** | 1.7 | (1.2) | 2.5 | (1.5) | 2.1 | (1.4) |
| NPI Euphoria | 0.5 | (0.8) | 0.6 | (0.8) | 0.5 | (0.8) |
| NPI Disinhibition | 0.5 | (0.9) | 0.7 | (1.4) | 0.5 | (1.2) |
| NPI Aberrant Motor | 2.6 | (1.7) | 3.3 | (1.9) | 2.9 | (1.8) |
| NPI Night Time | 2.3 | (1.7) | 2.7 | (1.5) | 2.5 | (1.6) |
| NPI Appetite/Eating | 0.7 | (1.0) | 1.0 | (1.5) | 0.9 | (1.2) |
*
p < 0.1 (italic font);
**
p < 0.05 (bold font).
Data are mean (SD) or frequency and percentage %. The frequency and percentages of incomplete variables are as follows: History of Personal Autoimmune Disease (n = 10; 12.2%), Serum Cytokines (n = 32; 39%), EEG Abnormal (n = 10; 12.2%), MRI Abnormal (n = 10; 12.2%), Lumbar Puncture Abnormal (n = 10; 12.2%), and Any Neurodiagnostic Study Abnormal (n = 10; 12.2%). Δ = difference between. Multiple responses allotted for types of trigger and psychotropic medications at baseline.